Cargando…
Erratum: A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081484/ https://www.ncbi.nlm.nih.gov/pubmed/35527350 http://dx.doi.org/10.1002/jev2.12219 |
Ejemplares similares
-
A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants
por: Jiang, Linglei, et al.
Publicado: (2022) -
A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants
por: Jiang, Linglei, et al.
Publicado: (2022) -
Engineering Extracellular Vesicles to Target Pancreatic Tissue In Vivo: Erratum
por: Komuro, Hiroaki, et al.
Publicado: (2023) -
Erratum: Airway T cells protect against RSV infection in the absence of antibody
por: Kinnear, E, et al.
Publicado: (2017) -
Erratum: Arrdc4‐dependent extracellular vesicle biogenesis is required for sperm maturation
Publicado: (2021)